- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00749736
The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.
The Role of Vitamin D in Immune Function in Patients With CKD Stages 3 and 4.
Patients with chronic kidney disease (CKD) are commonly deficient in vitamin D, with low levels of both calcidiol (25 hydroxy vitamin D) and calcitriol (1,25-hydroxy vitamin D). Patients with CKD are also known to have abnormalities in their immune cells, increased susceptibility to infection and increased prevalence of malignancies. In patients without kidney disease, repletion of vitamin D appears to help some immune mediated diseases. Thus it is logical that patients with CKD who are vitamin D deficient may benefit from repletion of vitamin D, in either its native form (cholecalciferol/ergocalciferol) or in the form of calcitriol or its analogues. However, no interventional data demonstrates that repletion positively impacts immune status in CKD patients. To test this hypothesis, a large interventional study will be required. However, prior to conducting this study, several important steps are needed. The present proposal aims to generate the necessary data to appropriately plan and conduct a future multi center interventional study. Specifically, we will examine the following specific aims in a population of CKD stage 3 and 4 subjects from Indiana University Affiliated Nephrology Clinics and determine
- if abnormalities in immune cells and immune blood tests are related to abnormalities in vitamin D.
- how reproducible these changes are on repeat testing and
- if repletion of vitamin D changes these cells and immune blood tests in a small pilot study.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Indiana University School of Medicine
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- no administration of any form of vitamin D supplement or therapy in the last 60 days except for that in a multi vitamin
- Hgb >10 mg/dl
- able to sign informed consent
- CKD stage 3 (GFR 30-59ml/min) or stage 4 (GFR 15-29ml/min)
- iPTH <70pg/ml for stage 3 or iPTH <110pg/ml for stage 4
- calcidiol levels < or +20ng/ml
Exclusion Criteria:
- initial corrected Calcium >9.7mg/dl
- initial serum Phosphorus >5.0mg/dl
- initial standardized blood pressure of >160/100
- history of significant liver disease or cirrhosis
- anticipated requirement for dialysis in 6 months
- malabsorption, severe chronic diarrhea, or ileostomy
- no calcimimetic or active vitamin D therapy 60 days prior to enrollment
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: 1
4000 IU of cholecalciferol per day
|
4000 IU of cholecalciferol per day 15 patients will be enrolled in each arm. |
Aktiv komparator: 2
1 mcg of doxercalciferol per day.
|
1 mcg of doxercalciferol per day
|
Placebo komparator: 3
placebo for six months
|
placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula. 15 patients will be enrolled in each arm. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
The primary endpoint will be the change in CD4+/CD8+ ratio and other flow cytometry parameters based on the results of Aims 1 and 2, TH1/TH2 cytokine profile, and conversion from anergic to reactive skin testing.
Tidsramme: 6 months from baseline visit
|
6 months from baseline visit
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
A change in mean blood pressure from one week of ambulatory measures, random protein/creatinine ratio, and differences in muscle strength by timed up and go test, and measures of quality of life using the SF36 forms.
Tidsramme: 6 months from baseline visit.
|
6 months from baseline visit.
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Sharon M Moe, MD, Indiana University School of Medicine
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 0707-04
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kronisk nyre sykdom
-
Clínica de Oftalmología de Cali S.AFullførtMeibomian kjerteldysfunksjon | Eyes Dry ChronicColombia
-
Medical University of ViennaFullførtSekundær hyperparathyroidisme | CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder | NyreerstatningØsterrike
-
Alcon ResearchFullført
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgia
-
Occyo GmbHUniversity Clinic for Ophthalmology and Optometry- SalzburgFullførtLimbal stamcelle mangel | Hornhinnesykdom | Eyes Dry Chronic | Kronisk konjunktivitt i begge øyne | Øyelesjon | Øyesykdom; Grå stær | Øyne Tørr følelse av | Hornhinne betent | Hornhinne; Skade, slitasje | HornhinneinfeksjonØsterrike
-
Novartis PharmaceuticalsTilgjengeligPrimær myelofibrose (PMF) | Polycytemi Vera (PV) | Post polycytemi myelofibrose (PPV MF) | Trombocytemi myelofibrose (PET-MF) | Alvorlig/svært alvorlig COVID-19-sykdom | Steroid Refractory Acute Graft Versus Host Disease (SR aGVHD) | Steroid Refractory Chronic Graft Versus Host Disease (SR cGVHD)
Kliniske studier på cholecalciferol
-
King Faisal Specialist Hospital & Research CenterFullført
-
Saiful Anwar HospitalFullført
-
University Hospital, Clermont-FerrandCRINEX Laboratory; BP 337 - 3 rue de Gentilly; 92541 MONTROUGE Cedex FRANCEUkjentLeddgikt | Vitamin D-mangelFrankrike
-
Hospital Infantil de Mexico Federico GomezRekrutteringVitamin D-mangel | Cystisk fibrose | Cystisk fibrose Lungeforverring | Cystisk fibrose hos barn | Bentetthet, lav | Kronisk betennelseMexico
-
Bispebjerg HospitalRigshospitalet, DenmarkUkjent
-
Karaganda Medical UniversityFullførtKronisk obstruktiv lungesykdom | Kronisk obstruktiv lungesykdom Moderat | Kronisk obstruktiv lungesykdom AlvorligKasakhstan
-
Instituto Nacional de Ciencias Medicas y Nutricion...UkjentNyreinsuffisiens | Vitamin D-mangel | Sluttstadium nyresvikt ved dialyse | Vaskulær forkalkningMexico
-
Shanghai Jiao Tong University School of MedicineHar ikke rekruttert ennå